Literature DB >> 28065856

Hypoxia promotes mitochondrial glutamine metabolism through HIF1α-GDH pathway in human lung cancer cells.

Zi-Feng Jiang1, Min Wang2, Jian-Lin Xu3, Ya-Jing Ning4.   

Abstract

Drug-resistance is common in human lung cancer therapy. Hypoxia remarkably contributes to drug-resistance in lung cancer but the underlying mechanism remains elusive. Here we demonstrate that hypoxia-induced glutamine metabolism is involved in drug resistance in lung cancer cells. Hypoxia increases glutamine up-take, glutamate to α-ketoglutarate flux and the generation of ATP in lung cancer cells by up-regulating the expression of glutamate dehydrogenase (GDH). Hypoxia-induced expression of GDH relies on the up-regulation of HIF1α but not HIF2α. HIF1α binds the promoter of GDH and promotes the transcription of GDH gene in lung cancer cells. Finally, we show that GDH represses cisplatin-induced cell apoptosis and repression of colony formation, indicating that GDH contributes to drug-resistance in lung cancer cells. In conclusion, HIF1α-GDH pathway regulates glutamine metabolism and ATP production upon hypoxia stress and contributes to drug-resistance in human lung cancer cells.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cisplatin; GDH; Glutamine; HIF; Hypoxia; Lung cancer

Mesh:

Substances:

Year:  2017        PMID: 28065856     DOI: 10.1016/j.bbrc.2017.01.015

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing.

Authors:  Vinod S Bisht; Kuldeep Giri; Deepak Kumar; Kiran Ambatipudi
Journal:  Cancer Biol Ther       Date:  2021-10-25       Impact factor: 4.742

2.  Neutral Desorption Extractive Electrospray Ionization Mass Spectrometry Analysis Sputum for Non-Invasive Lung Adenocarcinoma Detection.

Authors:  Qiaoling Zheng; Jianyong Zhang; Xinchen Wang; Wenxiong Zhang; Yipo Xiao; Sheng Hu; Jianjun Xu
Journal:  Onco Targets Ther       Date:  2021-01-15       Impact factor: 4.147

Review 3.  Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs" of Radiotherapy.

Authors:  Andria Rakotomalala; Alexandre Escande; Alessandro Furlan; Samuel Meignan; Eric Lartigau
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-02       Impact factor: 5.555

Review 4.  Therapeutic Potential of Glutamine Pathway in Lung Cancer.

Authors:  Enyu Tang; Siyang Liu; Zhiming Zhang; Rixin Zhang; Dejing Huang; Tong Gao; Tianze Zhang; Guangquan Xu
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

Review 5.  Effect of glutamine metabolism on chemoresistance and its mechanism in tumors.

Authors:  Xinyang Hu; Hongchuan Jin; Liyuan Zhu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-02-25

6.  Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft.

Authors:  Santosh K Bharti; Yelena Mironchik; Flonne Wildes; Marie-France Penet; Eibhlin Goggins; Balaji Krishnamachary; Zaver M Bhujwalla
Journal:  Oncotarget       Date:  2018-02-24

7.  Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.

Authors:  F Peng; J-H Wang; W-J Fan; Y-T Meng; M-M Li; T-T Li; B Cui; H-F Wang; Y Zhao; F An; T Guo; X-F Liu; L Zhang; L Lv; D-K Lv; L-Z Xu; J-J Xie; W-X Lin; E W-F Lam; J Xu; Q Liu
Journal:  Oncogene       Date:  2017-11-06       Impact factor: 9.867

8.  Dormancy and NKG2D system in brain metastases: Analysis of immunogenicity.

Authors:  Charlotte Flüh; Victor Mafael; Vivian Adamski; Michael Synowitz; Janka Held-Feindt
Journal:  Int J Mol Med       Date:  2019-12-30       Impact factor: 4.101

9.  Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.

Authors:  Inge Oudaert; Hatice Satilmis; Philip Vlummens; Wouter De Brouwer; Anke Maes; Dirk Hose; Elke De Bruyne; Bart Ghesquière; Karin Vanderkerken; Kim De Veirman; Eline Menu
Journal:  J Exp Clin Cancer Res       Date:  2022-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.